Cargando…
Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial
OBJECTIVE: Polyethylene glycol loxenatide (PEG-Loxe) is a novel, once-weekly glucagon-like peptide 1 receptor agonist that is approved in doses of 0.1 mg and 0.2 mg for the treatment of type 2 diabetes mellitus (T2DM). However, no clinical trials have been designed to determine the effect of 0.3 mg...
Autores principales: | Cai, Hongyu, Chen, Qianqian, Duan, Yale, Zhao, Yue, Zhang, Xiujuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909427/ https://www.ncbi.nlm.nih.gov/pubmed/36777344 http://dx.doi.org/10.3389/fendo.2023.1106868 |
Ejemplares similares
-
Efficacy of polyethylene glycol loxenatide versus insulin glargine on glycemic control in patients with type 2 diabetes: a randomized, open-label, parallel-group trial
por: Zhang, Shuo, et al.
Publicado: (2023) -
Impact of polyethylene glycol loxenatide on cardiovascular outcomes in patients with type 2 diabetes: study protocol for a multicentre, randomised, double-blind, placebo-controlled trial (BALANCE-3)
por: Xie, Yun, et al.
Publicado: (2023) -
Polyethylene glycol loxenatide (PEX168) in subjects with renal impairment: A pharmacokinetic study
por: Wang, Jianwen, et al.
Publicado: (2019) -
Polyethylene Glycol Loxenatide (PEX-168) Reduces Body Weight and Blood Glucose in Simple Obese Mice
por: Wu, Yuting, et al.
Publicado: (2021) -
Protective Effects and Mechanisms of Polyethylene Glycol Loxenatide Against Hyperglycemia and Liver Injury in db/db diabetic Mice
por: Zhang, Yu, et al.
Publicado: (2021)